Earnings call transcript: Gentian Diagnostics Q2 2025 sees stock drop 7.89%

Gentian Diagnostics reported a 14% year-over-year sales increase to 43.6 million NOK in Q2 2025, with strong growth in the US market. However, its stock declined 7.89% following the announcement, driven by investor concerns over operational challenges, including production issues and raw material complications, which significantly reduced the gross margin to 44% from 64% in Q1 and impacted EBITDA. Management attributed these issues to 'one-off' events, stating they are resolved, and aims to restore gross margins to 55-60% while progressing its NT proBNP assay towards a 2026 commercial launch and expanding its US market presence.

Analysis

Gentian Diagnostics' Q2 2025 results present a conflicting narrative of strong top-line growth undermined by significant operational failures. The company reported a 14% year-over-year increase in sales to 43.6 million NOK, propelled by a 156% surge in the US market and a 31% growth in its key Cystatin C product. However, this revenue performance was completely overshadowed by a severe contraction in gross margin, which plummeted to 44% from 64% in the prior quarter. Management attributed this to 'one-off' production and raw material issues in April and May, which necessitated scrapping finished product. The market reacted negatively, with the stock declining 7.89%, signaling that investors are prioritizing profitability and operational execution over revenue expansion. While the company maintains a solid balance sheet with 80 million NOK in cash and an 85% equity ratio, and management guides for a margin recovery to 55-60%, the episode exposes a critical vulnerability in its production process. The forward outlook hinges on both this operational stabilization and the successful development of its NT proBNP assay, which is targeted for a 2026 commercial launch and represents a key potential growth catalyst.

Key Decisions for Investors

• Investors must weigh the robust 14% revenue growth and strong US expansion against the significant operational risk highlighted by the Q2 gross margin collapse to 44%.
• The investment thesis is now highly dependent on management's credibility and their ability to demonstrate the production issues were truly 'one-off' by restoring gross margins to the guided 55-60% range in the coming quarters.
• Monitor progress on the NT proBNP assay as its 2026 launch is a primary long-term value driver, but treat any further production disruptions as a significant red flag indicating systemic, rather than isolated, issues.
• Given the stock's 7.89% decline, the key decision is whether the current price sufficiently discounts the execution risk or if the margin compression signals a more persistent threat to profitability.